Interstitial Cystitis Differential Diagnoses

Sections

DDx

Diagnostic Considerations

Diagnosing interstitial cystitis remains difficult even more than a century after it was described by Skene, in 1887. No pathognomonic findings exist with regard to patient history, physical examination findings, laboratory findings, or cystoscopy findings. The exclusion of other clinical entities remains the foremost goal of the workup and evaluation of patients thought to have this condition.

A careful, complete, and empathetic history and physical examination are critical. Cystoscopy is an adjunctive, although important, study. The classic Hunner ulcer in the setting of a small-capacity bladder (ie, assessed under anesthesia) is rarely seen to confirm the diagnosis with certainty. Until interstitial cystitis is defined completely or a definitive marker becomes universally available, the diagnosis remains one of exclusion.

The differential diagnosis of urinary frequency, urgency, and/or pain includes the following types of conditions:

Infectious or inflammatory
Gynecologic
Urologic
Neurologic

Infectious or inflammatory conditions to consider include the following:

Recurrent urinary tract infection (UTI)
Urethral diverticulum
Infected Bartholin gland or Skene gland
Vulvovestibulitis
Tuberculous/eosinophilic cystitis
Vaginitis (eg, bacterial, viral [eg, herpes])
Schistosomiasis

Gynecologic causes to consider include the following:

Pelvic malignancy or mass (eg, fibroid, endometrioma)
Endometriosis
Mittelschmerz
Pelvic inflammatory disease
Genital atrophy

Urologic causes to consider include the following:

Bladder cancer or carcinoma in situ (CIS)
Radiation cystitis
Overflow incontinence
Acontractile detrusor
Prostatodynia
Chronic pelvic pain syndrome
Bladder outlet obstruction (eg, urinary retention with overflow incontinence)
Large postvoid residual volume
Open bladder neck (eg, intrinsic sphincteric deficiency, urolithiasis, urethritis)

Neurologic causes to consider include the following:

Neurogenic detrusor overactivity
Parkinson disease
Lumbosacral disk disease
Spinal stenosis
Spinal tumor
Multiple sclerosis
Cerebrovascular accident

Other possible diagnoses to consider include the following:

Dysfunctional voiding
Vulvodynia
Pelvic floor myalgia
Degenerative joint disease
Hernia
Inflammatory bowel disease
Gastrointestinal neoplasm
Diverticulitis
Adhesions from prior surgery

Clinically, the practitioner is somewhat obligated to consider these potential alternative diagnoses prior to diagnosing interstitial cystitis. The implications of a diagnosis of interstitial cystitis are profound in that it is a chronic condition without universally effective therapy.

Workup

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21(2):167-78. [Medline].
[Guideline] Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015 May. 193 (5):1545-53. [Medline]. [Full Text].
[Guideline] Cox A, Golda N, Nadeau G, Curtis Nickel J, Carr L, Corcos J, et al. CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J. 2016 May-Jun. 10 (5-6):E136-E155. [Medline]. [Full Text].
Hosseini A, Ehrén I, Wiklund NP. Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis. J Urol. 2004 Dec. 172(6 Pt 1):2261-5. [Medline].
Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012 Jun. 187(6):2243-8. [Medline].
Blalock EM, Korrect GS, Stromberg AJ, Erickson DR. Gene expression analysis of urine sediment: evaluation for potential noninvasive markers of interstitial cystitis/bladder pain syndrome. J Urol. 2012 Feb. 187(2):725-32. [Medline].
Grigorescu B, Powers K, Lazarou G. Update on Urinary Tract Markers in Interstitial Cystitis/Bladder Pain Syndrome. Female Pelvic Med Reconstr Surg. 2016 Jan-Feb. 22 (1):16-23. [Medline].
Kim J, Freeman MR. Antiproliferative factor signaling and interstitial cystitis/painful bladder syndrome. Int Neurourol J. 2011 Dec. 15(4):184-91. [Medline]. [Full Text].
Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 2009 Feb. 103(4):541-6. [Medline].
Chai TC, Zhang CO, Shoenfelt JL, Johnson HW Jr, Warren JW, Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol. 2000 May. 163(5):1440-4. [Medline].
Hunner GL. A rare type of bladder ulcer in women: Report of cases. J Boston Med Surg. 1915. 172:660-5.
Dyer AJ, Twiss CO. Painful bladder syndrome: an update and review of current management strategies. Curr Urol Rep. 2014 Feb. 15(2):384. [Medline].
Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994 Nov. 152(5 Pt 1):1641-5. [Medline].
Meares EM Jr. Interstitial cystitis--1987. Urology. 1987 Apr. 29(4 Suppl):46-8. [Medline].
Ford AP, Gever JR, Nunn PA, Zhong Y, Cefalu JS, Dillon MP, et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006 Feb. 147 Suppl 2:S132-43. [Medline]. [Full Text].
Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul. 176(1):367-73. [Medline].
Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology. 2007 Apr. 69(4 Suppl):24-33. [Medline].
Twiss C, Kilpatrick L, Craske M, Buffington CA, Ornitz E, Rodríguez LV. Increased startle responses in interstitial cystitis: evidence for central hyperresponsiveness to visceral related threat. J Urol. 2009 May. 181(5):2127-33. [Medline].
Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. J Urol. 2002 Jun. 167(6):2470-2. [Medline].
Peters KM, Jaeger C, Killinger KA, Rosenberg B, Boura JA. Cystectomy for ulcerative interstitial cystitis: sequelae and patients' perceptions of improvement. Urology. 2013 Oct. 82(4):829-33. [Medline].
Rofeim O, Hom D, Freid RM, Moldwin RM. Use of the neodymium: YAG laser for interstitial cystitis: a prospective study. J Urol. 2001 Jul. 166(1):134-6. [Medline].
Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol. 1998 May. 159(5):1479-82. [Medline].
Hillelsohn JH, Rais-Bahrami S, Friedlander JI, Okhunov Z, Kashan M, Rosen L. Fulguration for Hunner ulcers: long-term clinical outcomes. J Urol. 2012 Dec. 188(6):2238-41. [Medline].
Fall M, Oberpenning F, Peeker R. Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions?. Eur Urol. 2008 Jul. 54(1):65-75. [Medline].
Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012 Feb. 79(2):484.e7-484.e13. [Medline].
Nickel JC, Tripp DA, Pontari M, et al. Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. Can Urol Assoc J. 2011 Dec. 5(6):410-5. [Medline]. [Full Text].
Parsons CL, Boychuk D, Jones S, et al. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol. 1990 Jan. 143(1):139-42. [Medline].
Warren JW, Keay SK, Meyers D, Xu J. Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs. Urology. 2001 Jun. 57(6 Suppl 1):22-5. [Medline].
Lorenzo Gómez MF, Gómez Castro S. [Physiopathologic relationship between interstitial cystitis and rheumatic, autoimmune, and chronic inflammatory diseases]. Arch Esp Urol. 2004 Jan-Feb. 57(1):25-34. [Medline].
Elliott CS, Payne CK. Interstitial cystitis and the overlap with overactive bladder. Curr Urol Rep. 2012 Oct. 13(5):319-26. [Medline].
Konkle KS, Berry SH, Elliott MN, Hilton L, Suttorp MJ, Clauw DJ, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012 Feb. 187(2):508-12. [Medline]. [Full Text].
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011 Aug. 186(2):540-4. [Medline].
Lifford KL, Curhan GC. Prevalence of painful bladder syndrome in older women. Urology. 2009 Mar. 73(3):494-8. [Medline].
Berry SH, Bogart LM, Pham C, Liu K, Nyberg L, Stoto M. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. J Urol. 2010 May. 183(5):1848-52. [Medline].
Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol. 2013 Jan. 189(1):141-5. [Medline].
Close CE, Carr MC, Burns MW, Miller JL, Bavendam TG, Mayo ME, et al. Interstitial cystitis in children. J Urol. 1996 Aug. 156(2 Pt 2):860-2. [Medline].
Konkle KS, Berry SH, Elliott MN, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology Study. J Urol. 2012 Feb. 187(2):508-12. [Medline].
Bogart LM, Suttorp MJ, Elliott MN, et al. Validation of a quality-of-life scale for women with bladder pain syndrome/interstitial cystitis. Qual Life Res. 2011 Dec 7. [Medline].
Bogart LM, Suttorp MJ, Elliott MN, Clemens JQ, Berry SH. Validation of a quality-of-life scale for women with bladder pain syndrome/interstitial cystitis. Qual Life Res. 2012 Nov. 21(9):1665-70. [Medline].
Quillin RB, Erickson DR. Management of interstitial cystitis/bladder pain syndrome: a urology perspective. Urol Clin North Am. 2012 Aug. 39(3):389-96. [Medline].
Troxel WM, Booth M, Buysse DJ, Elliott MN, Suskind AM, Clemens JQ, et al. Sleep disturbances and nocturnal symptoms: relationships with quality of life in a population-based sample of women with interstitial cystitis/bladder pain syndrome. J Clin Sleep Med. 2014 Dec 15. 10 (12):1331-7. [Medline].
Keller ML, McCarthy DO, Neider RS. Measurement of symptoms of interstitial cystitis. A pilot study. Urol Clin North Am. 1994 Feb. 21(1):67-71. [Medline].
Goin JE, Olaleye D, Peters KM, Steinert B, Habicht K, Wynant G. Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale: implications for use in randomized clinical trials. J Urol. 1998 Mar. 159(3):1085-90. [Medline].
Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J Urol. 2005 Mar. 173(3):835-40. [Medline].
O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997 May. 49(5A Suppl):58-63. [Medline].
Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001 Jun. 57(6 Suppl 1):62-6. [Medline].
Gish BA. Interstitial cystitis/bladder pain syndrome: symptoms, screening and treatment. Nurs Womens Health. 2011 Dec. 15(6):496-507. [Medline].
Helwick C. Think Beyond the Bladder for Interstitial Cystitis Pain. Medscape Medical News. Available at https://www.medscape.com/viewarticle/887862. October 31, 2017; Accessed: November 2, 2017.
Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999 Feb. 161(2):553-7. [Medline].
Ackerman AL, Lee UJ, Jellison FC, Tan N, Patel M, Raman SS, et al. MRI suggests increased tonicity of the levator ani in women with interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2016 Jan. 27 (1):77-83. [Medline].
Ueda T, Nakagawa M, Okamura M, Tanoue H, Yoshida H, Yoshimura N. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int J Urol. 2008 Dec. 15(12):1039-43. [Medline].
Wennevik GE, Meijlink JM, Hanno P, Nordling J. The Role of Glomerulations in Bladder Pain Syndrome: A Review. J Urol. 2016 Jan. 195 (1):19-25. [Medline].
Aihara K, Hirayama A, Tanaka N, Fujimoto K, Yoshida K, Hirao Y. Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy. Int J Urol. 2009 Dec. 16(12):947-52. [Medline].
Lee JD, Lee MH. Activation of extrinsic apoptotic pathway from bladder biopsy in patients with interstitial cystitis/painful bladder syndrome. Urology. 2013 Dec. 82(6):1451.e7-1451.e11. [Medline].
Clemens JQ, Calhoun EA, Litwin MS, Walker-Corkery E, Markossian T, Kusek JW, et al. A survey of primary care physician practices in the diagnosis and management of women with interstitial cystitis/painful bladder syndrome. Urology. 2010 Aug. 76(2):323-8. [Medline]. [Full Text].
FitzGerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai TC. Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol. 2012 Jun. 187(6):2113-8. [Medline].
Groutz A, Blaivas JG, Chaikin DC, Resnick NM, Engleman K, Anzalone D, et al. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. J Urol. 2000 Sep. 164(3 Pt 1):698-701. [Medline].
Gordon B, Shorter B, Sarcona A, Moldwin RM. Nutritional considerations for patients with interstitial cystitis/bladder pain syndrome. J Acad Nutr Diet. 2015 Sep. 115 (9):1372-9. [Medline].
Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urol. 2007 Jul. 178(1):145-52. [Medline].
Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients. Female Pelvic Med Reconstr Surg. 2011 Jan. 17(1):36-9. [Medline].
Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int. 2012 Jun. 109(11):1584-91. [Medline].
Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep. 170(3):810-5. [Medline].
van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004 Aug. 172(2):533-6. [Medline].
Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010 May. 183(5):1853-8. [Medline]. [Full Text].
Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005 Dec. 174(6):2235-8. [Medline].
Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012 Oct. 188(4):1186-91. [Medline].
[Guideline] Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011 Jun. 185 (6):2162-70. [Medline].
Yang CC, Burks DA, Propert KJ, Mayer RD, Peters KM, Nickel JC. Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011 Mar. 185(3):901-6. [Medline].
Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011 May. 185(5):1716-21. [Medline].
Lai HH, Gardner V, Ness TJ, Gereau RW 4th. Segmental Hyperalgesia to Mechanical Stimulus in Interstitial Cystitis/Bladder Pain Syndrome - Evidence of Central Sensitization. J Urol. 2013 Dec 5. [Medline].
Charrua A, Pinto R, Taylor A, Canelas A, Ribeiro-da-Silva A, Cruz CD, et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol Urodyn. 2013 Dec 24. [Medline].
Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005 May. 173(5):1590-4. [Medline].
Guo C, Yang B, Gu W, Peng B, Xia S, Yang F. Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis. PLoS One. 2013. 8(12):e82591. [Medline].
Colaco MA, Evans RJ. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013 Oct. 14(5):442-7. [Medline].
Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2008 May. 19(5):717-21. [Medline].
Chintea CL, Belal M. Is there enough evidence for the use of intravesical instillations of glycosaminoglycan analogues in interstitial cystitis?. BJU Int. 2013 Feb. 111(2):192-3. [Medline].
Shao Y, Shen ZJ, Rui WB, Zhou WL. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology. 2010 Mar. 75(3):547-50. [Medline].
Cervigni M, Natale F, Nasta L, Mako A. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012 Sep. 23(9):1187-92. [Medline].
Nickel JC, Hanno P, Kumar K, Thomas H. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012 Jun. 79(6):1220-4. [Medline].
Mayer R, Propert KJ, Peters KM, et al. A randomized controlled trial of intravesical bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol. 2005 Apr. 173(4):1186-91. [Medline].
Reimer K, Fleischer W, Brögmann B, Schreier H, Burkhard P, Lanzendörfer A, et al. Povidone-iodine liposomes--an overview. Dermatology. 1997. 195 Suppl 2:93-9. [Medline].
Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L. Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003 Mar. 61(3):656-63. [Medline].
Chuang YC, Lee WC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009 Oct. 182(4):1393-400. [Medline].
Tanaka T, Nitta Y, Morimoto K, Nishikawa N, Nishihara C, Tamada S, et al. Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. BMC Urol. 2011 May 24. 11:11. [Medline]. [Full Text].
Gallego-Vilar D, García-Fadrique G, Povo-Martin I, Salvador-Marin M, Gallego-Gomez J. Maintenance of the response to dimethyl sulfoxide treatment using hyperbaric oxygen in interstitial cystitis/painful bladder syndrome: a prospective, randomized, comparative study. Urol Int. 2013. 90(4):411-6. [Medline].
Evans RJ. Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con. J Urol. 2012 Dec. 188(6):2044-5. [Medline].
Marcelissen T, Jacobs R, van Kerrebroeck P, de Wachter S. Sacral neuromodulation as a treatment for chronic pelvic pain. J Urol. 2011 Aug. 186(2):387-93. [Medline].
Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int. 2011 Apr. 107(8):1258-64. [Medline].
Chai TC, Zhang C, Warren JW, Keay S. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis. Urology. 2000 May. 55(5):643-6. [Medline].
Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol. 2003 Apr. 169(4):1369-73. [Medline].
Peters KM, Konstandt D. Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis. BJU Int. 2004 Apr. 93(6):777-9. [Medline].
Rajkumar GN, Conn IG. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction. Urology. 2004 Jul. 64(1):2-8. [Medline].
Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol. 2004 Dec. 172(6 Pt 1):2316-20. [Medline].
Rapp DE, Lucioni A, Katz EE, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology. 2004 Jun. 63(6):1071-5. [Medline].
Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015 Apr 24. [Medline].
Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013 Feb. 189(2):548-53. [Medline].
Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn. 2011 Jan. 30(1):93-6. [Medline].
Tirumuru S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J. 2010 Oct. 21(10):1285-300. [Medline].
Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistochemistry analysis. Urology. 2013 Dec. 82(6):1452.e1-6. [Medline].
Norus T, Fode M, Nordling J. Ileal conduit without cystectomy may be an appropriate option in the treatment of intractable bladder pain syndrome/interstitial cystitis. Scand J Urol. 2013 Sep 27. [Medline].
Nordling J, Blaivas JG. Should urinary diversion for bladder pain syndrome/interstitial cystitis include cystectomy?. J Urol. 2014 Feb. 191(2):293-5. [Medline].
[Guideline] Hanno PM, Burks DA, Clemens JQ, et al. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. American Urological Association. Available at https://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm. Accessed: September 21, 2015.
Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E. A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2013 Nov 26. [Medline].

Media Gallery

of 0

Author

Eric S Rovner, MD Professor, Department of Urology, Medical University of South Carolina College of Medicine

Eric S Rovner, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Clinical Urologists, American College of Surgeons, American Urological Association, International Continence Society, International Society of Urology, Society of Pelvic Reconstructive Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Justin D Ellett, MD, PhD Resident Physician, Department of Urology, Medical University of South Carolina College of Medicine

Justin D Ellett, MD, PhD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society for Microbiology, Association for Academic Surgery

Disclosure: Nothing to disclose.

Colin Murrah Goudelocke, MD Assistant Professor, Department of Urology, Medical University of South Carolina College of Medicine

Colin Murrah Goudelocke, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, Sexual Medicine Society of North America, Tennessee Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo.

Acknowledgements

Matthew Eskridge, MD Physician, Alliance Urology Specialists, Greensboro, NC

Matthew Eskridge, MD is a member of the following medical societies: American Urological Association and Christian Medical & Dental Society

Disclosure: Nothing to disclose.

Colin Goudelocke, MD, Physician, Academic Urology, Chattanooga, TN

Disclosure: Nothing to disclose.

Ricardo Sanchez-Ortiz, MD Assistant Professor of Urologic Oncology, University of Puerto Rico School of Medicine; Adjunct Assistant Professor, Department of Urology, The University of Texas MD Anderson Cancer Center

Ricarco Sanchez-Ortiz, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Interstitial Cystitis Differential Diagnoses

Diagnostic Considerations

About

Membership

Apps

WebMD Network

Editions

What to Read Next on Medscape

Interstitial Cystitis Differential Diagnoses

Diagnostic Considerations

References

Tables

Contributor Information and Disclosures

What would you like to print?

Find Us On

About

Membership

Apps

WebMD Network

Editions

What to Read Next on Medscape

Medscape Consult

Tools

Most Popular Articles